您当前的位置: 首页 > 资源详情

Biospace,11月15日,Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

编译者:YUTING发布时间:2021-11-21点击量:47 来源栏目:最新研究

Abingdon, Oxon, UK, 15November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines today announces that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19.

The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses. In addition to providing safety and tolerability data, early data on CD8+ T-Cell mediated immune responses as a surrogate of protection against COVID-19 will be provided. The trial will be conducted by Professor Blaise Genton, Principal Investigator, from the Center for Primary Care and Public Health at the University of Lausanne, Switzerland. The first patient is anticipated to receive their first dose of Emergex vaccine candidate at the start of January 2022.

A Phase I clinical trial (NCT04935801), named naNO-DENGUE, testing Emergex’s Dengue vaccine candidate is currently underway in Switzerland with all patients having received two vaccine doses.

Robin Cohen, Chief Commercial Officerat Emergex Vaccines, commented: “OurT Cell priming vaccines mayoffer significant benefits over current COVID-19 vaccines including longer lasting immunity and broader protection against new variants.We are proud to announce the initiation of this trial and look forwardto gathering data to support the development of this important next generationvaccine.”

Professor Blaise Genton, Principal Investigator for the trial from the Center for Primary Care and Public Health (Unisante) at the University of Lausanne, Switzerlandcommented: “Although current COVID-19 vaccines have made significant progress in reducing mortality and morbidity challenges still remain, especially with the development of new variants.Thisexciting new scientific approach to developing a vaccine against SARS-CoV-2 addresses the need to generate a T-Cell response to elicit long termimmunity.We look forward to evaluating the results as when they are available.”

提供服务:导出本资源
  1. 1 Nature,11月10日,Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility
  2. 2 11月10日_研究人员分析宿主基因对COVID-19严重程度和易感性的影响
  3. 3 11月11日_新冠药物Remestemcel-L二期临床的中期分析结果积极
  4. 4 11月11日_CDC呼吁制定通用口罩规定以减少新冠传播
  5. 5 SSRN,2月20日,Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study
  6. 6 SSRN,2月20日,Mental Health Problems and Social Media Exposure During COVID-19 Outbreak
  7. 7 SSRN,2月20日,Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources
  8. 8 SSRN,2月20日,Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China
  9. 9 Nature,11月10日,Mobility network models of COVID-19 explain inequities and inform reopening
  10. 10 1月27日_Nature报道中国新型冠状病毒最新研究进展:病毒传播速度有多快?
  1. 1 Phys.org,2月21日,Why natural killer cells react to COVID-19
  2. 2 ScienceDaily,2月18日,T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer
  3. 3 2月18日_研究发现伊维菌素对轻度至中度COVID-19无效
  4. 4 2月17日_抗磷脂自身抗体可使COVID-19患者出现血栓
  5. 5 2月21日_科学家合成SARS-CoV-2病毒颗粒并发现刺突蛋白的转换机制
  6. 6 2月16日_免疫细胞靶向的SARS-CoV-2蛋白会引发蝙蝠冠状病毒的反应
  7. 7 Sciencedaily,2月17日,Study strengthens case that vitamins cannot treat COVID-19
  8. 8 Medicalxpress,2月16日,Study suggests increased risk of mental health disorders after COVID-19 infection
  9. 9 2月17日_高水平雌激素和抗酸剂可降低COVID-19风险
  10. 10 2月17日_研究发现COVID-19疫苗可提供持久的保护以预防再感染

版权所有@2017中国科学院文献情报中心

制作维护:中国科学院文献情报中心信息系统部地址:北京中关村北四环西路33号邮政编号:100190